These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 30683945)

  • 1. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
    Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
    Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
    Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
    Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.
    Bergmann NC; Lund A; Gasbjerg LS; Jørgensen NR; Jessen L; Hartmann B; Holst JJ; Christensen MB; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2953-2960. PubMed ID: 30848791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
    Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes.
    Daousi C; Wilding JP; Aditya S; Durham BH; Cleator J; Pinkney JH; Ranganath LR
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):195-201. PubMed ID: 19178509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
    Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
    Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.
    Verdich C; Toubro S; Buemann B; Lysgård Madsen J; Juul Holst J; Astrup A
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1206-14. PubMed ID: 11477506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
    Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.
    Bagger JI; Holst JJ; Hartmann B; Andersen B; Knop FK; Vilsbøll T
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4541-52. PubMed ID: 26445112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate.
    Lavin JH; Wittert GA; Andrews J; Yeap B; Wishart JM; Morris HA; Morley JE; Horowitz M; Read NW
    Am J Clin Nutr; 1998 Sep; 68(3):591-8. PubMed ID: 9734735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gender on the acute effects of whey protein ingestion on energy intake, appetite, gastric emptying and gut hormone responses in healthy young adults.
    Giezenaar C; Luscombe-Marsh ND; Hutchison AT; Lange K; Hausken T; Jones KL; Horowitz M; Chapman I; Soenen S
    Nutr Diabetes; 2018 Jul; 8(1):40. PubMed ID: 30006513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
    Stensen S; Krogh LL; Sparre-Ulrich AH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Gasbjerg LS; Knop FK
    Diabetes Obes Metab; 2022 Sep; 24(9):1882-1887. PubMed ID: 35491518
    [No Abstract]   [Full Text] [Related]  

  • 20. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.